CRBPCorbus Pharmaceuticals Inc.Signing up patients
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
Oropharyngeal Carcinoma (OPC)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 260 (planned)
- Started
- Sep 29, 2026
- Main results expected
- Dec 2027
- Fully finished
- Mar 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response Rate (%)
Measured over: Up to 24 months
Overall Survival (months)
Measured over: Approximately 3 years from randomization
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07768189 · record last updated 2026-10-08 · checked 2026-11-09 15:47 UTC